Tag: TSX
-
Markets slip as oil prices gain 01-09-24
The TSX edged down this morning to 20992.21. TSX Venture also fell slightly to 554.52 and the CSE Composite joined this negative run to 171.62. Despite this market pessimism, oil prices rebounded slightly with WTI Crude rising 2.57% to $72.59 USD per barrel. Information Technology made the most progress this morning on the TSX. Invesque…
-
JP Morgan lead analyst pegs $150 price target for Brent Crude, are we in an oil markets supercycle?
Oil markets are making headlines, but if you have been a reader of Equity Guru, then you were given the heads up back in late July 2023. My outlook and technical analysis play by play was given in subsequent articles and chart attack videos. Our first target has been hit, and prices are pulling back…
-
Oil price to resume uptrend on EU embargo on Russian oil. $185 a barrel oil?
Rising oil prices have been the talk on the street. Both Wall and Main street. Investors and traders are betting on higher prices due to geopolitics, while main street is worried higher fuel costs will eat into their monthly income as the inflation and rising interest rates hit the middle class. I am here to…
-
PredictMedix (PMED.C), CFO SECRETLY SOLD SHARES??? (*CLICKBAIT*)
Ok weekenders, let’s talk PMED. For the newbies in the room, PMED is PredictMedix Inc, a biotech company Equity Guru’s been working with for the past little bit. (Of course, this doesn’t change the fact that we’re still big on holding people accountable – client or not. See recent example here.) PMED as a business…
-
TSX.V, CSE: Canadian venture capital markets declare “Trudeau Ethics Scandal” weak sauce!
Reading this week’s political headlines, you’d think the media had just unearthed hidden-camera footage of Prime Minister Justin Trudeau in a Shanghai strip bar – pockets bulging with gold coins – giving a hand-job to the CEO of the China Petroleum Corporation (中国石油天然气集团公司). “Will Trudeau take responsibility for ethics breach?” – Ottawa Citizen. “Trudeau violated…
-
Abattis Bioceuticals (ATT.C): A grift building over several years until regulators couldn’t ignore it anymore
Several years ago, when Equity.Guru boss Chris Parry was writing at Stockhouse, he was called out to a new client – a company called Abattis Bioceutical (ATT.C). Abattis execs had just signed a marketing deal with Stockhouse to help tell their story to investors, and were excited for what might follow. As Parry tells it,…